FDA approves Foundayo, a once-daily GLP-1 pill for obesity

The Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, for adults with obesity, or adults with overweight plus at least one weight-related medical condition, to be used along with a reduced-calorie diet and increased physical activity ^[1][3]. It is the first once-daily GLP-1 pill for weight loss that can be taken at any time of day without restrictions on food or water ^[1][4]. Lilly said prescriptions were being accepted immediately, with shipping beginning April 6 ^[1].

Foundayo is a small-molecule (non-peptide) GLP-1, a different chemical class from the peptide-based GLP-1 medicines such as Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) ^[1][3]. Dosing starts at 0.8 mg once daily, and the dose can be raised no sooner than every 30 days, up to a maximum of 17.2 mg once daily ^[3]. In Phase 3 trials Lilly tested capsules at doses up to 36 mg; the approved product is a tablet with doses up to 17.2 mg, which Lilly said are equivalent ^[4]. By comparison, oral semaglutide must be taken in the morning at least 30 minutes before any food or drink other than water ^[4].

In the ATTAIN-1 trial, 3,127 adults with obesity or overweight and without diabetes were followed for 72 weeks ^[1]. People taking the highest dose who stayed on treatment lost an average of 27.3 pounds (12.4% of body weight), compared with 2.2 pounds (0.9%) for placebo ^[1][3]. Counting all participants regardless of whether they completed the trial, the average loss was 25 pounds (11.1%), compared with 5.3 pounds (2.1%) for placebo ^[1][3]. STAT News described the trial result as 11.2% weight loss, slightly different from the 11.1% figure Lilly reported for all participants ^[4][1].

"People living with obesity need treatment options that meet them where they are," Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, said in Lilly's announcement, citing "an average of 12.4% weight loss at the highest dose in clinical trials" ^[1]. Lilly CEO David Ricks said fewer than 1 in 10 people who could benefit from a GLP-1 are taking one ^[1].

What it costs

Lilly said eligible patients with commercial insurance may pay as little as $25 per month using a savings card, and self-pay pricing starts at $149 per month for the 0.8 mg dose ^[1][2]. Regular self-pay prices are $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg per 30-day supply; through Dec. 31, 2026, the 2.5 mg and 5.5 mg doses are temporarily reduced to $149 and $199 ^[2]. Eligible Medicare Part D patients may be able to get Foundayo for $50 per month beginning as soon as July 1, 2026 ^[1][2].

The savings card excludes anyone enrolled in government-funded programs, including Medicare and Medicaid, and expires Dec. 31, 2026 ^[2]. STAT News reported that Lilly lowered its planned cash price from a range of $149 to $399 a month to as much as $299 a month for patients who keep renewing, after Novo Nordisk launched its Wegovy pill at a cash price of up to $299 ^[4].

Safety information

Foundayo carries a boxed warning that it may cause thyroid C-cell tumors, including thyroid cancer, and it should not be used with other GLP-1 receptor agonist medicines ^[1][3]. It is not known whether Foundayo is safe and effective in children ^[1]. Common side effects reported in trials include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas and hair loss ^[1][3]. The label also warns about pancreatitis, severe stomach problems, dehydration-related kidney problems, low blood sugar, serious allergic reactions, gallbladder problems and vision changes in people with type 2 diabetes ^[1]. Lilly said oral birth control pills may not work as well while taking Foundayo and that a pregnancy exposure registry will be established ^[1].

Why it matters for patients

A pill removes several practical barriers that come with injections: no needles, no refrigeration, and no need to time a dose around meals or water ^[1][4]. Novo Nordisk's Wegovy pill, approved in December 2025, led to 13.6% weight loss in a 64-week Phase 3 trial, slightly more than orforglipron's result in its 72-week study, and Novo has argued that its pill has a longer safety track record because it contains the same ingredient as injectable Wegovy ^[4]. STAT News reported that orforglipron did not show liver risks in its studies ^[4].

How widely insurers will cover Foundayo, and how the two oral GLP-1s compare head-to-head in real-world use, has not been reported. The approval came under the FDA's National Priority Voucher program, which grants faster reviews to drugs aligned with national health priorities ^[4]. STAT News reported that agency insiders have described the voucher program as a vehicle for political interference, and that Lilly received a voucher as part of a deal with the White House to lower prices of its obesity drugs in certain settings ^[4].

What happens next

Shipping through LillyDirect began April 6, with broad availability through U.S. retail pharmacies and telehealth providers expected shortly after ^[1]. Medicare Part D access at $50 per month could begin as soon as July 1, 2026 ^[1][2]. The savings card and the temporary self-pay price reductions run through Dec. 31, 2026 ^[2]. Lilly said it has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval, and the drug is also being studied for obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence ^[1].